Table 1.
Patient characteristics
| Number of patients with ≥1 alteration(s) (includes VUS) | 149 (70.0%) | ||
|---|---|---|---|
|
| |||
| Number of patients with ≥1 characterizeda alteration(s) (excludes VUS) | 123 (58%) | ||
|
| |||
| Median number of characterizeda alterations per patient (range) | 1 (0–13) | ||
|
| |||
| Women | Men | Overall | |
| Number | 89 (41.8%) | 124 (58.2%) | 213 |
| Age (median, range) | 60 (25–92) | 62 (29–88) | 61 (25–92) |
| Cancer Type (N, %)* | |||
| Colorectal Adenocarcinoma | 27 (49.1%) | 28 (50.9%) | 55 (25.8%) |
| Appendix Adenocarcinoma | 23 (50.0%) | 23 (50.0%) | 46 (21.6) |
| Hepatocellular Carcinoma | 8 (25.8%) | 23 (74.2%) | 31(14.6%) |
| Pancreatic Ductal Adenocarcinoma | 15 (60.0%) | 10 (40.0%) | 25 (11.7%) |
| Cholangiocarcinoma | 4 (30.8%) | 9 (69.2%) | 13 (6.1%) |
| Gastric Adenocarcinoma | 6 (54.5%) | 5 (45.5%) | 11 (5.2%) |
| Esophageal Adenocarcinoma | 0 | 8 (100.0%) | 8 (3.8%) |
| Gastrointestinal Stromal Tumor (GIST) | 0 | 7 (100.0%) | 7 (3.3%) |
| Pancreatic Neuroendocrine Tumor | 0 | 5 (100.0%) | 5 (2.3%) |
| Anal Carcinoma | 3 (75.0%) | 1 (25.0%) | 4 (1.9%) |
| Gallbladder Carcinoma | 2 (66.7%) | 1 (33.3%) | 3 (1.4%) |
| Duodenum Adenocarcinoma | 0 | 2 (100.0%) | 2 (0.9%) |
| GI Carcinoma Small Cell | 0 | 1 (100.0%) | 1 (0.5%) |
| Small bowel adenocarcinoma (small intestine) | 0 | 1 (100.0%) | 1 (0.5%) |
| Stomach carcinoma (Signet ring cell carcinoma) | 1 (100.0%) | 0 | 1 (0.5%) |
Abbreviations: VUS = Variant of unknown significance
a
Characterized alterations do not, by definition, include VUSs
*
Percentages for women and men are the percent of cases within a given cancer type.